Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100


Stage-specific sensitivity to p53 restoration during lung cancer progression.

Feldser DM, Kostova KK, Winslow MM, Taylor SE, Cashman C, Whittaker CA, Sanchez-Rivera FJ, Resnick R, Bronson R, Hemann MT, Jacks T.

Nature. 2010 Nov 25;468(7323):572-5. doi: 10.1038/nature09535.


Selective activation of p53-mediated tumour suppression in high-grade tumours.

Junttila MR, Karnezis AN, Garcia D, Madriles F, Kortlever RM, Rostker F, Brown Swigart L, Pham DM, Seo Y, Evan GI, Martins CP.

Nature. 2010 Nov 25;468(7323):567-71. doi: 10.1038/nature09526.


Requirement for NF-kappaB signalling in a mouse model of lung adenocarcinoma.

Meylan E, Dooley AL, Feldser DM, Shen L, Turk E, Ouyang C, Jacks T.

Nature. 2009 Nov 5;462(7269):104-7. doi: 10.1038/nature08462. Epub 2009 Oct 21.


CKIα ablation highlights a critical role for p53 in invasiveness control.

Elyada E, Pribluda A, Goldstein RE, Morgenstern Y, Brachya G, Cojocaru G, Snir-Alkalay I, Burstain I, Haffner-Krausz R, Jung S, Wiener Z, Alitalo K, Oren M, Pikarsky E, Ben-Neriah Y.

Nature. 2011 Feb 17;470(7334):409-13. doi: 10.1038/nature09673.


Restoration of p53 function leads to tumour regression in vivo.

Ventura A, Kirsch DG, McLaughlin ME, Tuveson DA, Grimm J, Lintault L, Newman J, Reczek EE, Weissleder R, Jacks T.

Nature. 2007 Feb 8;445(7128):661-5. Epub 2007 Jan 24.


p53 loss does not permit escape from BrafV600E-induced senescence in a mouse model of lung cancer.

Garnett S, Dutchak KL, McDonough RV, Dankort D.

Oncogene. 2017 Nov 9;36(45):6325-6335. doi: 10.1038/onc.2017.235. Epub 2017 Jul 24.


Context-Dependent Effects of Amplified MAPK Signaling during Lung Adenocarcinoma Initiation and Progression.

Cicchini M, Buza EL, Sagal KM, Gudiel AA, Durham AC, Feldser DM.

Cell Rep. 2017 Feb 21;18(8):1958-1969. doi: 10.1016/j.celrep.2017.01.069.


Suppression of lung adenocarcinoma progression by Nkx2-1.

Winslow MM, Dayton TL, Verhaak RG, Kim-Kiselak C, Snyder EL, Feldser DM, Hubbard DD, DuPage MJ, Whittaker CA, Hoersch S, Yoon S, Crowley D, Bronson RT, Chiang DY, Meyerson M, Jacks T.

Nature. 2011 May 5;473(7345):101-4. doi: 10.1038/nature09881. Epub 2011 Apr 6.


p53 suppresses carcinoma progression by inhibiting mTOR pathway activation.

Akeno N, Miller AL, Ma X, Wikenheiser-Brokamp KA.

Oncogene. 2015 Jan 29;34(5):589-99. doi: 10.1038/onc.2013.589. Epub 2014 Jan 27.


Tip60 is a haplo-insufficient tumour suppressor required for an oncogene-induced DNA damage response.

Gorrini C, Squatrito M, Luise C, Syed N, Perna D, Wark L, Martinato F, Sardella D, Verrecchia A, Bennett S, Confalonieri S, Cesaroni M, Marchesi F, Gasco M, Scanziani E, Capra M, Mai S, Nuciforo P, Crook T, Lough J, Amati B.

Nature. 2007 Aug 30;448(7157):1063-7.


Mutually exclusive inactivation of DMP1 and ARF/p53 in lung cancer.

Mallakin A, Sugiyama T, Taneja P, Matise LA, Frazier DP, Choudhary M, Hawkins GA, D'Agostino RB Jr, Willingham MC, Inoue K.

Cancer Cell. 2007 Oct;12(4):381-94.


TP53 Silencing Bypasses Growth Arrest of BRAFV600E-Induced Lung Tumor Cells in a Two-Switch Model of Lung Tumorigenesis.

Shai A, Dankort D, Juan J, Green S, McMahon M.

Cancer Res. 2015 Aug 1;75(15):3167-80. doi: 10.1158/0008-5472.CAN-14-3701. Epub 2015 May 22.


[Expression of protein p53 in the adenoma-colorectal carcinoma sequence].

Gafà R, Lanza G.

Pathologica. 1998 Aug;90(4):351-6. Italian.


Thrombospondin-1 mediates oncogenic Ras-induced senescence in premalignant lung tumors.

Baek KH, Bhang D, Zaslavsky A, Wang LC, Vachani A, Kim CF, Albelda SM, Evan GI, Ryeom S.

J Clin Invest. 2013 Oct;123(10):4375-89. doi: 10.1172/JCI67465. Epub 2013 Sep 9.


Mutation of TP53 and alteration of p14(arf) expression in EGFR- and KRAS-mutated lung adenocarcinomas.

Cortot AB, Younes M, Martel-Planche G, Guibert B, Isaac S, Souquet PJ, Commo F, Girard P, Fouret P, Brambilla E, Hainaut P, Soria JC.

Clin Lung Cancer. 2014 Mar;15(2):124-30. doi: 10.1016/j.cllc.2013.08.003. Epub 2013 Oct 26.


NKX2-1-mediated p53 expression modulates lung adenocarcinoma progression via modulating IKKβ/NF-κB activation.

Chen PM, Wu TC, Cheng YW, Chen CY, Lee H.

Oncotarget. 2015 Jun 10;6(16):14274-89.


miRNA-34 prevents cancer initiation and progression in a therapeutically resistant K-ras and p53-induced mouse model of lung adenocarcinoma.

Kasinski AL, Slack FJ.

Cancer Res. 2012 Nov 1;72(21):5576-87. doi: 10.1158/0008-5472.CAN-12-2001. Epub 2012 Sep 10.


p19Arf suppresses growth, progression, and metastasis of Hras-driven carcinomas through p53-dependent and -independent pathways.

Kelly-Spratt KS, Gurley KE, Yasui Y, Kemp CJ.

PLoS Biol. 2004 Aug;2(8):E242. Epub 2004 Aug 17.

Supplemental Content

Support Center